PPARG and type 2 diabetes mellitus: Because of the importance of insulin sensitizers in the treatment of T2D, new-generation insulin sensitizers classified as direct PPARγ agonists, selective PPARγ modulators, and PPARγ-sparing compounds are in development [130].